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NUP98 – a novel predictor of response to
anthracycline-based chemotherapy in triple
negative breast cancer
Paul B. Mullan1, Victoria Bingham1, Paula Haddock2, Gareth W. Irwin1,3, Elaine Kay4, Stephen McQuaid1 and
Niamh E. Buckley2*
Abstract
Background: Triple Negative breast cancer (TNBC) is a poor outcome subgroup of breast cancer defined based on
the absence of expression of ERα and PR and HER2 amplification. These hard to treat cancers lack targeted
treatment options and are therefore treated with a standard of care (SoC) generic cocktail of DNA damaging
chemotherapy, with a wide range of clinical responses. While a subset of TNBC patients respond very well to this
treatment, others receive no clinical benefit and die from their disease within a short time period. We currently lack
biomarkers to prospectively identify patients likely to relapse and we lack alternate treatment options.
Methods: NUP98 protein expression was investigated in patient samples using two independent tissue microarrays
(TMAs), as well as a normal breast TMA. Correlation with pathological response to various chemotherapy regimens
was investigated.
Results: We have shown that high NUP98 is significantly associated with poor outcome in TNBC patient samples
both by gene expression and IHC-based protein analysis. While trends linking NUP98 expression with poorer
outcomes were observed in breast cancer overall (and more specifically in the LuminalB Her2- subgroup), significant
correlations were observed in TNBC. This appeared to be specific to anthracycline based regimens as the association
between NUP98 and response was not observed in patients treated with taxane-based chemotherapy.
Conclusions: We have identified a novel biomarker, NUP98, that can predict response to anthracycline based
chemotherapy in TNBC. The ability to prospectively identify patients who are less likely to respond to SoC
chemotherapy is a vital step in improving the overall survival of these patients.
Keywords: Triple negative breast cancer, NUP98, Biomarker, Chemotherapy
Background
Breast cancer is a heterogeneous disease comprised of
multiple tumour subtypes that require different treatment
approaches and have varied patient outcomes. Patient
stratification, based on the expression of the estrogen re-
ceptor (ERα) or amplification of the Her2/neu/ERBB2
(HER2) receptor, has facilitated the use of targeted therap-
ies such as Tamoxifen and Trastuzumab, respectively.
Breast cancers that do not express these receptors (as well
as the Progesterone receptor (PR)) are termed “triple
negative breast cancers” (TNBCs) and have the poorest
clinical outcome, reflecting, in part, the fact that they lack
targeted therapies. These hard to treat cancers are there-
fore treated with a SoC cocktail of DNA-damaging
chemotherapies (e.g. FEC: 5-Fluorouracil, Epirubicin and
Cyclophosphamide) with limited clinical response.
TNBCs display a unique clinical profile with very high
risk of recurrence observed in the first 3 years following
diagnosis, which then drops quickly to a rate lower than
patient with non-TNBCs [1, 2]. While TNBC in general
is associated with the poorest clinical outcome,
neo-adjuvant studies have shown that there are at least 2
distinct subgroups of TNBC; one group displaying
pathological complete response (pCR) following treatment
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and excellent survival rate comparable to non-TNBC
cases with pCR. The second group, displaying residual dis-
ease (RD) following treatment, have much poorer out-
come compared to non-TNBC with only 68% of patients
alive 3 years post-treatment compared to 88% [2]. This
demonstrates that overall survival in TNBC is intrinsically
linked to the response to first line chemotherapy. How-
ever, we currently lack biomarkers to prospectively iden-
tify which patients are likely to respond to SoC and which
are not and should have an alternate treatment plan.
Numerous studies have attempted to define further mo-
lecular subgroups within TNBC using unsupervised clus-
tering of gene expression data in order to improve clinical
outcome and identify novel treatment options and are
summarised in [3]. In this study we instead used a super-
vised approach to identify genes associated with outcome
in a cohort of TNBC all treated with SoC FEC chemother-
apy [4]. We identified and validated the nuclear pore pro-
tein, NUP98, as a novel biomarker associated with poor
outcome in TNBC in the context of SoC anthracycline
based treatment. NUP98 has an established role in cancer
as a fusion partner associated with leukaemogeneis. Con-
versely, it has been proposed as a tumour suppressor in
liver cancer. Here we propose a novel oncogenic role for
NUP98 in TNBC and highlight the potential utility not
only as a biomarker in the context of SoC chemotherapy
but also in novel targeted treatment strategies.
Methods
Gene expression analysis: The QUB TNBC gene expres-
sion dataset has been previously described [4]. Public
datasets, GSE6861, 7390, 9574, 22,093 and 20,271 were
accessed online using NCBI. The ElasticNet regularization
procedure was performed using the R package “glmnet”
[5]. The optimal lambda (0.3) was chosen based on a
10-fold cross-validation. The ElasticNet regularization is a
convex combination of the ridge and the lasso penalty
with a weighting parameter “alpha”. Bootstrapping (× 100)
followed by a hypergeometric test to identify non-random
features was used for feature selection.
Survival Analysis: All Kaplan Meier analysis and Haz-
ard Ratio Calculations were carried out using the R
package “Survival”. Multivariate analysis was carried out
using the clinical parameters: age, tumour grade, lymph
node involvement, Lymphovascular invasion and chemo-
therapy regimen (in the case of the 2nd TNBC TMA).
Tissue microarrays (TMAs) and immunohistochemistry (IHC)
The breast cancer TMAs used in this study were
constructed from formalin-fixed paraffin-embedded
(FFPE) primary tumour blocks by the Northern Ireland
Biobank with each tumour sample represented by three
independent 1 mm diameter cores. The full breast cohort
[6] and the 2nd TNBC TMA [7] have been previously
described with additional information provided in Add-
itional file 1 Table S1.
The normal breast TMA consisted of 40 FFPE samples
collected from reduction mammoplasty and/or normal
adjacent tissue to cancer within Beaumont Hospital,
Dublin. Whole face sections of the FFPE samples were
stained with haematoxylin and eosin (H&E) to select
epithelial rich regions for targeted coring. All cases were
reviewed by an experienced breast histopathologist. The
TMA was constructed using a manual tissue arrayer
(Beecher Instruments, Silver Spring, MD, USA) with
1-mm-diameter tissue cores from donor blocks inserted
into recipient blocks with each patient sample repre-
sented by three independent cores.
IHC was performed in a hybrid laboratory (Northern
Ireland Molecular Pathology Laboratory) that has UK Clin-
ical Pathology Accreditation, and the infrastructure to
process both clinical patient samples and research mate-
rials. Sections were cut from the TMA blocks for H&E
staining and IHC. The initial section was used for H&E
staining to assess TMA quality and appropriate tumour
content for subsequent IHC localization and analysis. Sec-
tions for IHC were cut at 4 μm on a rotary microtome,
dried at 37 °C overnight, and then used for IHC, performed
on an automated immunostainer (Leica Bond-Max, Milton
Keynes, UK). Repeat ERα, PR and HER2 IHC were per-
formed to confirm the triple negative status all samples in
the TMA as previously described [6]. The 2 NUP anti-
bodies were validated in-house using positive and negative
whole-face breast cancer sections identified through gene
expression. Antigen-binding sites were detected with a
polymer-based detection system (Bond, Newcastle Upon
Tyne, UK, Cat. No. DS 9800). All sections were visualized
with diaminobenzidine, counterstained with haematoxylin,
and mounted in DPX. Biomarker conditions were as fol-
lows. NUP98 - rabbit polyclonal antibody, LSBIO #B10323
was used at a 1:200 dilution with epitope retrieval solution
1 pre-treatment for 20 mins. NUP96 - rabbit monoclonal
(clone EPR6678) antibody LSBIO #C138875 was used at a
1:50 dilution with epitope retrieval solution 2 for 20 mins.
Scoring and assessment
Only cores with identifiable tumour as confirmed by
pathology assessment of H&E slides were used in IHC
analysis. All IHC was scored independently by at least
two experienced immunohistochemists (SMcQ, NB, VB)
blinded to patient clinicopathological and outcome data.
Expression of both biomarkers was exclusively confined
to the tumour epithelial cells. Individual TMA cores
were scored as absent/low (0), intermediate [1], or high
[2] expression of NUP98 based on intensity of staining.
Statistical Analysis: Statistical Analysis was carried out
using GraphPad Prism (v6.0). All relevant data was
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analysed by two-tailed Students t-test or one-way Anova
as required. Quantification of the relationship between
NUP98 and pathological outcome was performed using
contingency tables and analysis by Fisher’s exact test or
chi-square test as appropriate. All data was deemed sig-
nificant with a p-value of at least < 0.05 with * indicating
a p-value < 0.05, ** a p-value of < 0.01 and *** a p-value
of < 0.001.
Results
In order to identify genes associated with good (no relapse
within 3 years post treatment) and poor (relapse within 3
years post treatment) outcome in TNBC, we used an
elasticnet-based approach to identify genes whose expres-
sion was differentially associated with outcome in a cohort
of 60 TNBC cases all treated with SoC chemotherapy
(FEC). NUP98 was identified with significantly higher ex-
pression in the poor outcome samples (Figure 1a). Fur-
thermore, high NUP98 expression (above the median) was
also shown to be significantly associated with worse re-
lapse free survival (RFS) using both univariate (HR 2.87
(95% CI 1.118–7.447) p = 0.0285) and multivariate (HR
4.885 (95% CI 1.6520–14.453) p = 0.00414) analysis,
independent of all clinical variables (Fig. 1a and Tables 1
and 2). A similar trend was observed for overall survival
(OS) though this did not reach significance (Additional file
2 Figure S1). However, given the fact that there is no cure
for secondary breast cancer and time to death following
relapse is shorter in TNBC compared to other types of
breast cancer [1], it can be assumed that given a longer
follow-up period, the findings for OS would mirror those
seen for RFS.
In order to further investigate the potential role for
NUP98 as a biomarker of response to SoC, we next opti-
mised and validated a commercially available antibody
for use on tissue microarrays (TMAs) to assess NUP98
protein expression by immunohistochemistry (IHC). We
first utilised a TMA with matched samples to the gene
expression study. A range of expression of NUP98 was
observed with low/absent (score = 0), intermediate
(score = 1) and high (score = 2) expression patterns ob-
served (Figure 2a). When staining was present, a
A
B
Fig. 1 a Box and whisker plot of NUP98 gene expression in good and
poor outcome samples in the in-house TNBC gene expression dataset. b
Kaplan Meier plot of relapse free survival dichotomised based on NUP98
gene expression above (high) and below the median (low)
Table 1 Cox Proportional Hazard ratios, 95% Confidence intervals
(95%CI) and p-values for survival analysis of relapse free and
overall survival dichotomised based on below (low) and above
(high) the median gene expression of NUP98
Relapse Free Survival N(n) HR %95 CI p-value
Univariate 60 (21)
Nup98 low 30 (6) 1
high 30 (15) 2.8856 1.118–7.447 0.0285*
Multivariate
Nup98 low 30 (6) 1
high 30 (15) 4.885 1.6520–14.453 0.00414 **
Overall Survival 60 (16)
Nup98 low 30 (6) 1
high 30 (10) 1.808 0.6738–4.791 0.2430
Table 2 Clinical characteristics of the NUP98 high and low
samples within the in-house TNBC gene expression datasets
Nup98 low (N = 30) Nup98 high (N = 30)
Age < 40 3 5
40–49 11 12
50–59 6 6
60+ 10 7
T code 1 11 9
2–4 19 21
N code 0 18 21
1–3 12 9
LVI present 14 15
Not seen 16 15
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Fig. 2 a Representative images demonstrating scoring strategy with (i) absent (score = 0), (ii) low (score = 1) and (iii) high (score = 2) NUP98 IHC
expression. b Representative images of NUP98 staining at (i) × 20 and (ii) × 40 magnification. c (i) Representative image of absence of staining for
NUP98 in normal breast tissue. (ii) Box and whisker plot of NUP98 expression in normal and cancer breast samples from publicly available dataset
GSE9574. d Representative images at (i&ii) × 10 and (iii) × 40 magnification of NUP98 expression in DCIS
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Fig. 3 (See legend on next page.)
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punctate cytoplasmic pattern was observed within the
epithelial compartment with most of the cells staining to
a similar extent (Figure 2b). We also investigated NUP98
expression in a small TMA of normal breast tissue (N =
40) with no expression of NUP98 observed other than a
rare cell with weakly positive staining in the nucleus
(Figure 2c (i)). This was consistent with the statistically
higher NUP98 expression observed in cancer vs normal
samples from a publicly available dataset [8] (Figure 2c
(ii)). Of interest, a few examples of DCIS were available
for analysis within cores on the breast cancer TMA.
NUP98 was expressed on the DCIS component of these
cases (Figure 2d), suggesting that this is an early event in
cancer.
Consistent with the gene expression analysis, any (inter-
mediate or high) NUP98 protein expression was associ-
ated with an almost significant worse relapse free survival
(HR 6.707 (95%CI 0.8815–51.04) p = 0.066) (Figure 3a (i),
Table 3a). Interestingly, this appeared to be a graduated ef-
fect with the highest NUP98 expression most significantly
associated with poor outcome (HR 10.373 (95%CI
1.3035–82.54) p = 0.0271) (Figure 3a (ii), Table 3b). As
seen with the gene expression data, a trend towards over-
all survival was also observed (Additiona file 2 Figure S1B,
Table 2b).
Given the significant association between NUP98 and
survival, we went on to validate our findings in a second
independent TNBC cohort [7] as outlined in the RE-
MARK guidelines [9]. A similar expression pattern was
observed with low, intermediate and high expression (data
not shown). Furthermore, a similar association between
NUP98 expression and survival was observed with the
highest expression associated with the worst survival
which trended towards significance in a univariate analysis
but did reach significance when analysed in a multivariate
fashion (HR 8.95 (95%CI 1.06–75.11) p = 0.0433)(Figure
3b, Table 3c). Similar, though non-significant results were
also seen when analysed for overall survival (Additional
file 2 Figure S1C, Table 2d).
Four isoforms of NUP98 are present in human cells,
all generated by alternate splicing of the gene [10]. Iso-
forms 1 and 4 are generated through splicing at exon 20
followed an unusual biogenesis pathway in which a large
precursor protein is produced. This is then proteolytic-
ally cleaved to produce both NUP98 and NUP96 [11].
Isoforms 2 and 3 are generated without splicing at exon
20 and do not encode NUP96. As it was not possible to
distinguish between isoforms through gene expression
analysis or IHC, we also assessed NUP96 expression in
our TNBC TMA to determine whether NUP96 was also
associated with outcome. NUP96 was expressed in 19%
of cases with a nuclear pattern of expression within the
epithelial compartment with little variety in staining in-
tensity (Figure 3c). Therefore, samples were designated
as present or absent for NUP96 expression. There was
no significant association between NUP96 expression
and survival (Figure 3d, Additional file 2 Figure S1D,
Table 3e).
We next wanted to investigate whether the role for
NUP98 as a biomarker to predict response to SoC was re-
stricted to TNBC or could be applied to breast cancer as a
whole. We therefore utilised the full cohort (N = 300)
from which our original TNBC cases had been selected
which represents breast cancer as a whole [6]. NUP98 was
expressed (regardless of intensity) in the vast majority of
cases (90%) with a punctate cytoplasmic pattern observed
consistent with our previous TMA cohorts. However, the
distribution of NUP98 expression varied significantly
(chi-squared p = < 0.0001) between subtypes of breast can-
cer (defined by the St Gallen surrogate classification
method [12]) with only the TNBC samples showing a sub-
stantial proportion of samples with no NUP98 expression
(Figure 4A). NUP98 protein expression was then analysed
in the context of survival in breast cancer as a whole as
well as within the subtypes (Figures 4b-f). In general, high
NUP98 expression was associated with worse outcome.
Similar to our findings in TNBC (Figure 3a (ii)), high
NUP98 expression was also associated with worse out-
come in the Luminal B,HER2 negative subgroup. How-
ever, the graduation effect observed with intermediate
expression was not seen (Figure 4d). Interestingly, in the
HER2 enriched subgroup, high NUP98 expression was
associated with a more favourable outcome indicating a
unique role in this subgroup (Figure 4f). Due to the vary-
ing results in the different molecular subgroups, we fo-
cussed our subsequent investigations on TNBC as this
demonstrated the most significant findings.
Considering that all patients within our discovery (and
most in the validation) cohort were treated with chemo-
therapy, we wanted to ascertain whether the association
with NUP98 and survival was purely prognostic or predict-
ive of response to treatment with SoC chemotherapy. Using
the online tool, KM Plotter [13], a significant association
with poor relapse free survival and high NUP98 expression
was only observed when patients who did not receive sys-
temic treatment were excluded in both breast cancer as a
(See figure on previous page.)
Fig. 3 a Kaplan Meier plot of relapse free survival stratified based on (i) presence or absence, (ii) or absent (0), low (1) or high (2) NUP98 IHC
expression in the in-house TNBC TMA1 with matched gene expression. b Kaplan Meier plot of relapse free survival stratified based on absent (0),
low (1) or high (2) NUP98 IHC expression in the in-house TNBC TMA2. c Representative images of NUP96 staining at (i) × 10 and (ii) × 40
magnification. d Kaplan Meier plot of relapse free survival stratified based on presence or absence of NUP96
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Table 3 (A) Cox Proportional Hazard ratios, 95% Confidence intervals (95%CI) and p-values for survival analysis of relapse free
survival dichotomised based on presence or absence and of NUP98 IHC expression in the in-house TNBC TMA1 with matched gene
expression. (B) Cox Proportional Hazard ratios, 95% Confidence intervals (95%CI) and p-values for univariate and multivariate survival
analysis of relapse free and overall survival stratified based on absent (0), low (1) or high (2) NUP98 IHC expression in the in-house TNBC
TMA1 with matched gene expression. Cox Proportional Hazard ratios, 95% Confidence intervals (95%CI) and p-values for univariate and
multivariate survival analysis of (C) relapse free and (D) overall survival stratified based on absent (0), low (1) or high (2) NUP98 IHC
expression in the in-house TNBC TMA2. (E) Cox Proportional Hazard ratios, 95% Confidence intervals (95%CI) and p-values for survival
analysis of relapse free survival dichotomised based on presence or absence and of NUP96 IHC expression in the in-house TNBC TMA2
A
TNBC TMA #1 N(n) HR %95 CI p-value
Relapse Free Survival 53(16) Univariate
Nup98 absent 15 (1) 1
present 37 (14) 6.707 0.8815–51.04 0.066
B
TNBC TMA #1 N(n) HR %95 CI p-value
Relapse Free Survival 53(16) Univariate
Nup98 low 15 (1) 1
medium 19 (5) 4.24 0.495–36.33 0.1871
high 18 (9) 10.373 1.3035–82.54 0.0271*
Relapse Free Survival Multivariate
Nup98 low 15 (1) 1
medium 19 (5) 3.7522 0.41815–33.670 0.2375
high 18 (9) 13.32 1.39448–127.242 0.0245*
Overall Survival 53 (12) Univariate
Nup98 low 15 (1) 1
medium 19 (3) 2.5638 0.266–24.65 0.415
high 18 (6) 5.8375 0.7016–47.57 0.103
C
TNBC TMA #2 N(n) HR %95 CI p-value
Relapse Free Survival 63(24) Univariate
Nup98 low 10 (1) 1
medium 34 (14) 5.044 0.6629–38.38 0.1181
high 19 (9) 7.293 0.9324–57.04 0.0583
Multivariate
Nup98 low 10 (1) 1
medium 34 (14) 4.39 0.051–37.87 0.1783
high 19 (9) 8.95 1.06–75.11 0.0433*
D
TNBC TMA #2 N(n) HR %95 CI p-value
Relapse Free Survival 63(24) Univariate
Nup98 low 10 (1) 1
medium 34 (14) 5.086 0.6685–38.70 0.1162
high 19 (9) 6.558 0.8293–51.86 0.0747
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whole (Figure 5a) and TNBC (Figure 5b, Table 4). This was
confirmed using analysis the TRANSBIG study, a dataset of
early breast cancer where patients received no cytotoxic
chemotherapy [14], where no association between NUP98
expression and RFS, DMFS or OS was observed (Figure 5c
(i)-(iii)). These results indicated that NUP98 expression was
predictive of outcome only in the context of chemotherapy.
In order to understand if this was specific to the type of
chemotherapy given, we analysed a dataset where patients
were neo-adjuvantly treated with either a non-taxane-
(FEC) or taxane-based (TET) regimen [15]. A highly signifi-
cant association between NUP98 expression and patho-
logical complete response (pCR) (p = 0.0057) was observed
in patients treated with FEC – patients with low NUP98
expression were over twice as likely to achieve pCR as pa-
tients with high NUP98. No association between NUP98
expression and response to TET was observed (Table 5 and
Additional file 1 Table S2). Similar results were seen in
other neo-adjuvant cohorts treated with FEC or FAC
[16, 17] (Table 5 and Additional file 1 Table S1) indi-
cating a role for NUP98 in predicting response to
non-taxane, anthracycline based chemotherapy.
Discussion
In this study we have identified NUP98 as a novel bio-
marker of response to SoC, DNA-damaging chemother-
apy in TNBC. We have shown that both higher gene
and protein expression are associated with poor clinical
outcome in TNBC. Investigation into the role of NUP98
as a biomarker in breast cancer as a whole showed simi-
lar trends to TNBC especially within Luminal B,HER2
negative cases. Using publicly available data, we could
show that NUP98 did not predict response in the ab-
sence of systemic treatment or in the context of
taxane-based chemotherapy but was highly predictive of
response to anthracycline based regimens.
The nucleoporin protein, NUP98, is an essential part
of the nuclear pore complex (NPC); a very large (> 100
MDa) protein complex involved in the transport of mol-
ecules across the nuclear envelope. Nucleoporins are
one of four key factors affecting nuclear transport. The
role of these as well as Ran, karyopherin and NLS/NES
are reviewed elsewhere [18, 19]. NUP98 is a peripheral
nucleoporin and found on both the nuclear and cyto-
plasmic sides of the NPC [10] and is thought to have dif-
ferent functions depending on binding partners, such as
NUP88 and NUP96 which are found on the cytoplasmic
and nuclear sides of the NPC, respectively [20]. NUP98
has also been shown to interact with RAE1 and play an
important role in the export of mRNA from the nucleus
[21]. In addition to its role in nuclear transport, NUP98
has been shown to play an important role in gene
regulation through its ability to dynamically interact
with the genome and regulate chromatin structure
and transcriptional memory [22–25]. Furthermore, it
is involved in mitosis though regulation of the ana-
phase promoting complex and microtubule dynamics
[26, 27].
Table 3 (A) Cox Proportional Hazard ratios, 95% Confidence intervals (95%CI) and p-values for survival analysis of relapse free
survival dichotomised based on presence or absence and of NUP98 IHC expression in the in-house TNBC TMA1 with matched gene
expression. (B) Cox Proportional Hazard ratios, 95% Confidence intervals (95%CI) and p-values for univariate and multivariate survival
analysis of relapse free and overall survival stratified based on absent (0), low (1) or high (2) NUP98 IHC expression in the in-house TNBC
TMA1 with matched gene expression. Cox Proportional Hazard ratios, 95% Confidence intervals (95%CI) and p-values for univariate and
multivariate survival analysis of (C) relapse free and (D) overall survival stratified based on absent (0), low (1) or high (2) NUP98 IHC
expression in the in-house TNBC TMA2. (E) Cox Proportional Hazard ratios, 95% Confidence intervals (95%CI) and p-values for survival
analysis of relapse free survival dichotomised based on presence or absence and of NUP96 IHC expression in the in-house TNBC TMA2
(Continued)
Multivariate
Nup98 low 10 (1) 1
medium 34 (14) 4.71 0.552–40.11 0.1566
high 19 (9) 7.91 0.94–66.62 0.0570
E
TNBC TMA #2 N(n)
53(16)
HR %95 CI p-value
Relapse Free Survival
Nup96 absent 53(21) 1
present 11(5) 1.378 0.4839–4.234 0.5173
Overall Survival
Nup96 absent 53 (20) 1
present 11 (5) 1.418 0.4943–4.445 0.04825*
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The first link between NUP98 and cancer came from
its identification as a fusion partner with HOXA9 in
AML patients [28, 29]. Since then, multiple other fusion
partners (e.g. JARID1A and SETBP1) have been identi-
fied in multiple types of haematological malignancies
(reviewed in [30, 31]). The known functions of these fu-
sion partners implicate the change in chromatin struc-
ture and subsequent regulation of transcription in
NUP98-induced leukemogenesis.
NUP98 itself has also been shown to play an import-
ant role in regulating the nuclear to cytoplasmic
trafficking of GALECTIN3, a oncogene with known
roles in cell growth, adhesion, migration, invasion,
angiogenesis and apoptosis [32]. More recently, a study
has revealed novel role for NUP98 as a potential tumour
suppressor in hepatic cancer [33]. Here the authors
showed that NUP98 functions during genotoxic stress to
protect specific p53-induced targets (such as p21WAF1
and 14–3-3σ) from exosome-dependent degradation by
binding to the 3’UTR of the p53 target gene. Loss of
NUP98 resulted in decreased p21WAF1 expression and
reduced senescence in response to genotoxic stress
A B
C D
E F
Fig. 4 a Percentage distribution of NUP98 IHC expression in breast cancer overall, as well as subtypes defined by the St Gallen Classification method
in the full Breast (N = 300) cohort. b-f Kaplan Meier plots of relapse free survival stratified based on absent (0), low (1) or high (2) NUP98 IHC expression
in the St Gallen subgroups with the full Breast cohort
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which could in turn lead to tumourigenesis though loss
of wild-type p53 function. They went on to show that
NUP98 mRNA expression is reduced in patient samples
and correlated with p21WAF1 expression. Our findings,
however, indicate an oncogenic role for NUP98 and this
may be due to the fact that, in contrast to liver cancer,
the vast majority (> 80%) of TNBC cases harbour gain of
function p53 mutations [34, 35]. It is possible that, in
this scenario, NUP98 functions to stabilise a subset of
mutant p53 target genes and thus promote tumour re-
sistance to chemotherapy. This may also underpin the
association between NUP98 and poor outcome in pa-
tients with LuminalB,HER2- disease as this subgroup is
known to harbour high p53 mutation rates relative to
LuminalA (41% vs 17% respectively) [36]. Further studies
involving RNA-IP would be required to identify poten-
tial mutant p53 target genes and assess their role in re-
sponse to treatment and tumourigenesis. Furthermore,
the cytoplasmic pattern of expression observed in our
TNBC cases differs from the normal expression pattern
of NUP98 where it is confined to the NPC or nucleo-
plasm. This suggests loss of its normal functions in
A
B
C
Fig. 5 Kaplan Meier plot of relapse free survival dichotomised based on NUP98 expression above (high) and below the median (low) in (a)(i) all
breast cancer samples, (a)(ii) all breast cancer samples excluding patients without systemic chemotherapy treatment, (b)(i) all TNBC samples and
(b)(ii) all TNBC samples excluding patients without systemic chemotherapy treatment using KMplotter. c Kaplan Meier plot of (i) relapse free, (ii)
overall survival and (iii) distant metastasis free survival in the systemically untreated early breast cancer TRANSBIG cohort (GSE7390)
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regulation of chromatin structure and nuclear transport
in favour of its potential “mRNA chaperone” function.
The potential interplay between NUP98 and mutant
p53 may also explain why NUP98 does not predict re-
sponse to taxane based regimens. A number of studies
have shown that mutant p53 confers resistance to
anthracyclines [37, 38], while not changing [39] or in-
creasing sensitivity [40] to taxanes. This was tested in a
phase III randomised clinical trial but failed to demon-
strate predictive power [41]. However, the yeast assay
used to determine p53 status does not distinguish be-
tween different types of p53 mutations and therefore a
sequencing approach would be required to determine if
a specific gain of function effect was present. Further-
more, while the main analysis focussed on breast can-
cer as a whole, varied responses were seen when
analysed in the context of breast cancer subtypes,
with TNBC showing a different trend to the other
subgroups [15]. This subtype dependent effect has
also been observed in other studies [42] and is
consistent with the correlation between NUP98 and
survival in the different subtypes.
Overall this study highlights the potential role for
NUP98 as a biomarker of response to SoC chemother-
apy in TNBC. To the best of our knowledge, this is the
first time NUP98 (as opposed to a fusion partner) has
been associated with poor outcome, suggesting an onco-
genic role for the protein in this context. Other members
of the nucleoporin family have been linked with cancer in-
cluding Tpr, NUP62, NUP214 and NUP358/RanBP2 [31]
with NUP88 and more recently, NUP43 specifically linked
to poor outcome in breast cancer [43, 44]. Analysis of our
TNBC cohort shows that while there was no correlation
between NUP98 and NUP43 expression, NUP43 is associ-
ated with good outcome both in terms of higher expres-
sion (p = 0.0015) and RFS (HR3.53 (95%CI 1.478–7.99) p
= 0.0045) (Additional file 3 Figure S2B). This observation
warrants further analysis in a future study to delineate the
factors underpinning the differing results and the signifi-
cance of NUP43 as a potential biomarker in breast cancer.
Table 4 Cox Proportional Hazard ratios, 95% Confidence intervals (95%CI) and p-values for survival analysis of relapse free survival
dichotomised based on NUP98 expression above (high) and below the median (low) in (A)(i) all breast cancer samples, (A)(ii) all
breast cancer samples excluding patients without systemic chemotherapy treatment, (B)(i) all TNBC samples, (A)(ii) all TNBC samples
excluding patients without systemic chemotherapy treatment
KMplotter
Relapse Free Survival
N(n) HR %95 CI p-value
All Breast Cancer All Samples
Nup98 low 1984(671) 1
high 1984(602) 0.95 00.85–1.06 0.37
All Breast Cancer Untreated cases excluded
Nup98 low 940 (291) 1
high 940 (333) 1.35 1.15–1.58 0.00016***
TNBC All Cases
Nup98 low 128 (37) 1
high 128 (47) 1.37 0.89–2.09 0.15
TNBC Untreated cases excluded
Nup98 low 58 (13) 1
high 58 (25) 2.07 1.05–3.97 0.025*
Table 5 Statistical analysis of the correlation between NUP98 expression (dichotomised based on NUP98 expression above (high)
and below the median (low)) and pathological response in publicly available neo-adjuvant datasets (GSE6861, GSE22093 and
GSE20271)
Relative Risk Odd’s Ratio Chi-Squared
p-value
Fisher’s exact
p-value
GSE6861 FEC 2.5 4.8 0.0028 0.0057**
GSE6861 TET 1.277 1.481 0.3544 0.4018
GSE22093 FEC/FAC 1.289 2.67 0.0317 0.0463*
GSE20271 FEC/FAC 1.702 3.506 0.0323 0.0483*
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Conclusion
In conclusion we have identified a novel biomarker that
can predict response to anthracycline based chemotherapy
in TNBC. The ability to prospectively identify patients
who are less likely to respond to SoC chemotherapy is a
vital step in improving the overall survival of these pa-
tients. Furthermore, given the significant expression of
NUP98 in both DCIS and invasive breast cancer relative
to normal breast provides further utility for this biomarker
in the early diagnosis of the disease. Further understanding
of the molecular mechanisms of the role of NUP98 in
tumourigenesis and how it modulates response to treatment
may provide novel treatment strategies to personalise treat-
ment and improve the outcomes for women with TNBC.
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Additional file 1: Table S1. Clinical and pathological data of patient
samples within the 2nd TNBC cohort. Table S2. Contingency table of
NUP98 expression (dichotomised based on NUP98 expression above
(high) and below the median (low)) and pathological response in
publicly available neo-adjuvant datasets (GSE6861, GSE22093 and
GSE20271). (PPTX 69 kb)
Additional file 2: Figure S1. (A) Kaplan Meier plot of overall survival of
TNBC patients from in-house datasets dichotomised based on NUP98
gene expression above (high) and below the median (low). (B) Kaplan
Meier plot of overall survival stratified based on absent (0), low (1) or high
(2) NUP98 IHC expression in the TNBC TMA with matched gene expression.
(C) Kaplan Meier plot of overall survival stratified based on absent (0), low (1)
or high (2) NUP98 IHC expression in the 2nd TNBC TMA. (D) Kaplan Meier
plot of overall survival stratified based on presence or absence of NUP96.
(PPTX 170 kb)
Additional file 3: Figure S2. (A) Kaplan Meier plot of overall survival
dichotomised based on NUP88 gene expression above (high) and below
the median (low) in the in-house TNBC gene expression dataset.(B) Box
and whisker plot of NUP43 gene expression in good and poor outcome
samples in the in-house TNBC gene expression dataset. (C) Kaplan Meier
plot of relapse free survival dichotomised based on NUP43 gene expression
above (high) and below the median (low) in the in-house TNBC gene
expression dataset. (PPTX 156 kb)
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